
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF346 (zinc finger protein 346) encodes a nucleolar zinc finger protein that preferentially binds double-stranded RNA and RNA/DNA hybrids. Its zinc finger domains contribute to RNA binding and nucleolar localization, supporting a role in RNA-associated cellular processes. ZNF346 may also influence cell growth and survival and has been reported to protect neurons from inappropriate cell-cycle re-entry by promoting expression of the cell-cycle inhibitor p21.
A human hepatocellular carcinoma model, MHCC97-H was established from a highly metastatic human hepatocellular carcinoma and selected for its invasive and metastatic phenotype. The cells originated from a liver tumor of a 39-year-old male and are classified as a human liver cancer cell line. MHCC97-H is characterized by a hypotriploid karyotype and has been used in studies of hepatocellular carcinoma invasion and metastasis.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 1
Reference Transcript: NM_001308213
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?